Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Initial search results include only NCI-sponsored clinical trials. To search all trials, click the "REFINE SEARCH" button, scroll down to the Trial ID/Sponsor section and select the "All" check box in the Sponsor of Trial section.

View Content for:
Display:
?
Cancer Type/Condition:  Lymphoma, AIDS-related
Stage/Subtype:  AIDS-related peripheral/systemic lymphoma
Country:  U.S.A.
Trial Type:  Treatment
Trial Status:  Active
Results 1-24 of 24 for your search:
Start Over
Stem Cell Transplant for Hematological Malignancy
Phase: Phase III
Type: Treatment
Status: Active
Age: 54 and under
Sponsor: Other
Protocol IDs: 0107M05202, MT2001-02, NCT00176930
Biological Therapy in Treating Patients at High-Risk or With Lymphoma, Lymphoproliferative Disease, or Malignancies
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: Not specified
Sponsor: NCI, Other
Protocol IDs: 95-024, P30CA008748, MSKCC-95024, NCI-V95-0685, NCT00002663
Vorinostat and Pegylated Liposomal Doxorubicin in Relapsed or Refractory Lymphomas
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 0711003269, NCT00785798
Phase 1/2 Dose Escalation and Efficacy Study of Anti-CD38 Monoclonal Antibody in Patients With Selected CD38+ Hematological Malignancies
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: TED10893, U1111-1116-5472, NCT01084252
Autologous Peripheral Stem Cell Transplant in Treating Patients With Non-Hodgkin's Lymphoma or Hodgkin's Lymphoma
Phase: Phase II
Type: Treatment
Status: Active
Age: Under 70
Sponsor: Other
Protocol IDs: 2005LS048, UMN-0508M72589, UMN-MT2004-24, UMN-2005LS048, NCT00345865
A-dmDT390-bisFv(UCHT1) Immunotoxin Therapy for Patients With Cutaneous T-Cell Lymphoma (CTCL)
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: FDA IND 100712, NCT00611208
Immune Response After Stem Cell Transplant in HIV-Positive Patients With Hematologic Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 75 and under
Sponsor: NCI, Other
Protocol IDs: 2212.00, NCI-2009-01244, P30CA015704, U19AI096111, P01CA018029, NCT00968630
CD34+Selection for Partially Matched Family or Matched Unrelated Adult Donor Transplant
Phase: Phase II
Type: Treatment
Status: Active
Age: 0 to 26
Sponsor: Other
Protocol IDs: L 10,321, NYMC 525, NCT01049854
Rasburicase in Patients at High Risk for Tumor Lysis Syndrome (TLS) During Cycle-2
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: Not specified
Sponsor: Other
Protocol IDs: 2010-0284, NCI-2012-01889, NCT01200485
Ofatumumab and Bendamustine Hydrochloride With or Without Bortezomib in Treating Patients With Untreated Follicular Non-Hodgkin Lymphoma
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2011-02625, CDR0000694298, CALGB 50904, U10CA180821, U10CA031946, NCT01286272
Umbilical Cord Blood Transplantation In Patients With Hematologic Malignancies Using A Myeloablative Preparative Regimen
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 21 and under
Sponsor: Other
Protocol IDs: UCBT01, NCI-2011-03700, NCT01328496
Sirolimus or Vorinostat and Hydroxychloroquine in Advanced Cancer
Phase: Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 2010-0588, NCI-2011-00303, NCT01266057
Belinostat for Solid Tumors and Lymphomas in Patients With Varying Degrees of Hepatic Dysfunction
Phase: Phase I
Type: Biomarker/Laboratory analysis, Supportive care, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: 110060, 11-C-0060, NCT01273155
A Study Of PF-05082566 As A Single Agent And In Combination With Rituximab
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: B1641001, 2011-002799-17, NCT01307267
Administration of TAA-Specific CTLs; Hodgkin or Non-Hodgkin Lymphoma; TACTAL
Phase: Phase I
Type: Treatment
Status: Active
Age: Any age
Sponsor: NCI, Other
Protocol IDs: H-27471-TACTAL, TACTAL, NCT01333046
Phase I Study of Pazopanib and Vorinostat
Phase: Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 2011-0051, NCI-2011-00771, NCT01339871
The First-in-human Phase I Trial of PU-H71 in Patients With Advanced Malignancies
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 11-041, NCT01393509
Romidepsin in Treating Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Solid Tumors With Liver Dysfunction
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2012-01040, NCI-2013-01545, CDR0000737061, J11105, 9008, P30CA006973, U01CA132123, U01CA062505, U01CA069912, U01CA070095, UM1CA186644, UM1CA186686, UM1CA186690, UM1CA186691, UM1CA186717, NCT01638533
Ibrutinib in Treating Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma in Patients With HIV Infection
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2014-00707, AMC-091, U01CA121947, NCT02109224
Fludarabine and Total-Body Irradiation Followed By Donor Stem Cell Transplant and Cyclosporine and Mycophenolate Mofetil in Treating HIV-Positive Patients With or Without Cancer
Phase: No phase specified
Type: Treatment
Status: Active
Age: Under 65
Sponsor: NCI, Other
Protocol IDs: 1410.00, NCI-2010-00802, P30CA015704, P01CA018029, FHCRC-1410.00, NCT00112593
Proton Radiation for Lymphoma Involving Mediastinum
Phase: No phase specified
Type: Treatment
Status: Active
Age: 6 and over
Sponsor: Other
Protocol IDs: 12-346, NCT01751412
Dose Adjusted EPOCH-R, to Treat Mature B Cell Malignancies
Phase: No phase specified
Type: Treatment
Status: Active
Age: 21 and under
Sponsor: NCI, Other
Protocol IDs: H-30759, DA-EPOCH-R, DA-EPOCH-R, 5K12CA090433-12, NCT01760226
Gene Therapy After Frontline Chemotherapy in Treating Patients With AIDS-Related Non-Hodgkin Lymphoma
Phase: No phase specified
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 to 65
Sponsor: NCI, Other
Protocol IDs: 13282, NCI-2013-01728, NCT01961063
Start Over